Lung cancer surgery is evolving rapidly, faster than we could imagined a few years ago. This rapid development is related to the following observations: (I) in many countries, the tumor profile has changed dramatically, with an increasing rate of ground glass opacities and cancers detected at an early stage. This evolution is partly due to the screening programs and to the strong demand from patients and their doctors to have a CT-scan; (II) when a small suspicious pulmonary nodule is discovered, the patient legitimately asks about the most effective treatment but also the less invasive one. Surgery is now competing with other treatments, in particular stereotactic radiotherapy (SBRT) or radiofrequency whose mortality is close to zero with a morbidity comprised between 1% and 2% (1). Thus, although SBRT may have a slightly higher local recurrence rate than surgical resection and lower survival, this very low morbidity may make it the technique of choice in elderly and/ or fragile patients (2). In the near future, some small tumors may also be destroyed endoscopically using Electromagnetic Navigation Bronchoscopy. Engineers are actively working on it. Driven by these developments, the dogma of "lobectomy as standard treatment" for all non-small cell lung cancers (NSCLC), regardless of patient's age and profile, is faltering. As written by Cao, some surgeons now ask themselves the question "Could less be more?" (3). Indeed, although results of randomized trials are still pending (4,5), several recent studies seem to indicate that oncology results and survival of LRTs are equivalent to those of lobectomies for early stage NSCLC (6-8), while morbidity is much lower (9), especially when the procedure is performed via a closed chest approach (10). Finally, in 2018, more and more surgeons are choosing to treat a small tumor with a sublobar resection and the majority agree that the maximum benefit of the procedure is obtained when done by thoracoscopy. The current concern is that thoracoscopic